SomnoMed (ASX:SOM) said its revenue for the quarter ended Dec. 31, 2024, grew 20% year-over-year to AU$28.5 million, according to a Friday Australian bourse filing.
Its revenue in the fiscal second quarter reported a jump in all geographies, with North America and Asia-Pacific achieving double-digit increases.
It updated its guidance for the fiscal year ending June 30, now expecting a revenue of about AU$105 million as well as earnings before interest, taxes, depreciation, and amortization of between AU$7 million to AU$9 million.
The firm's shares rose 10% in recent trading on Friday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.